Selected research
Market Outlook & Growth Opportunities
Global Hereditary Disease Testing Market Outlook and Growth Opportunities 2026
Market perspective
The global Hereditary Disease Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Hereditary Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hereditary Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hereditary Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Hereditary Disease Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Hereditary Disease Testing market include Myriad Genetics, Invitae, Illumina, Natera, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche, Quest Diagnostics, CooperSurgical and Agilent Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Hereditary Disease Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hereditary Disease Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hereditary Disease Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hereditary Disease Testing market.
Hereditary Disease Testing Segment by Company
Myriad Genetics
Invitae
Illumina
Natera
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche
Quest Diagnostics
CooperSurgical
Agilent Technologies
Thermo Fisher Scientific
Twist Bioscience
Sophia Genetics
Fulgent Genetic
Medgenome
CENTOGENE
Hereditary Disease Testing Segment by Type
Hereditary Cancer Testing
Hereditary Non-cancer Testing
Hereditary Disease Testing Segment by Application
Hospital
Clinic
Laboratory
Others
Hereditary Disease Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Hereditary Disease Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Hereditary Disease Testing key companies, revenue, market share, and recent developments.
3. To split the Hereditary Disease Testing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Hereditary Disease Testing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Hereditary Disease Testing significant trends, drivers, influence factors in global and regions.
6. To analyze Hereditary Disease Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hereditary Disease Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hereditary Disease Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hereditary Disease Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hereditary Disease Testing industry.
Chapter 3: Detailed analysis of Hereditary Disease Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Hereditary Disease Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Hereditary Disease Testing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Hereditary Disease Testing Industry Trends
Table 2. Hereditary Disease Testing Industry Drivers
Table 3. Hereditary Disease Testing Industry Opportunities and Challenges
Table 4. Hereditary Disease Testing Industry Restraints
Table 5. Global Hereditary Disease Testing Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Hereditary Disease Testing Revenue Share by Company (2021-2026)
Table 7. Global Hereditary Disease Testing Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Hereditary Disease Testing Key Company Manufacturing Base & Headquarters
Table 9. Global Hereditary Disease Testing Company, Product Type & Application
Table 10. Global Hereditary Disease Testing Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Hereditary Disease Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Hereditary Cancer Testing
Table 15. Significant Companies of Hereditary Non-cancer Testing
Table 16. Global Hereditary Disease Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Hereditary Disease Testing Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Hereditary Disease Testing Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Hereditary Disease Testing Sales Value Share by Type (2021-2026)
Table 20. Global Hereditary Disease Testing Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Hospital
Table 22. Significant Companies of Clinic
Table 23. Significant Companies of Laboratory
Table 24. Significant Companies of Others
Table 25. Global Hereditary Disease Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 26. Global Hereditary Disease Testing Sales Value by Application (2021-2026) & (US$ Million)
Table 27. Global Hereditary Disease Testing Sales Value by Application (2027-2032) & (US$ Million)
Table 28. Global Hereditary Disease Testing Sales Value Share by Application (2021-2026)
Table 29. Global Hereditary Disease Testing Sales Value Share by Application (2027-2032)
Table 30. Global Hereditary Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. Global Hereditary Disease Testing Sales Value by Region (2021-2026) & (US$ Million)
Table 32. Global Hereditary Disease Testing Sales Value Share by Region (2021-2026)
Table 33. Global Hereditary Disease Testing Sales Value by Region (2027-2032) & (US$ Million)
Table 34. Global Hereditary Disease Testing Sales Value Share by Region (2027-2032)
Table 35. Global Hereditary Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 36. Global Hereditary Disease Testing Sales Value by Country (2021-2026) & (US$ Million)
Table 37. Global Hereditary Disease Testing Sales Value Market Share by Country (2021-2026)
Table 38. Global Hereditary Disease Testing Sales Value by Country (2027-2032) & (US$ Million)
Table 39. Global Hereditary Disease Testing Sales Value Market Share by Country (2027-2032)
Table 40. Myriad Genetics Company Information
Table 41. Myriad Genetics Business Overview
Table 42. Myriad Genetics Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 43. Myriad Genetics Hereditary Disease Testing Product Portfolio
Table 44. Myriad Genetics Recent Development
Table 45. Invitae Company Information
Table 46. Invitae Business Overview
Table 47. Invitae Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 48. Invitae Hereditary Disease Testing Product Portfolio
Table 49. Invitae Recent Development
Table 50. Illumina Company Information
Table 51. Illumina Business Overview
Table 52. Illumina Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Illumina Hereditary Disease Testing Product Portfolio
Table 54. Illumina Recent Development
Table 55. Natera Company Information
Table 56. Natera Business Overview
Table 57. Natera Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 58. Natera Hereditary Disease Testing Product Portfolio
Table 59. Natera Recent Development
Table 60. Laboratory Corporation of America Holdings Company Information
Table 61. Laboratory Corporation of America Holdings Business Overview
Table 62. Laboratory Corporation of America Holdings Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 63. Laboratory Corporation of America Holdings Hereditary Disease Testing Product Portfolio
Table 64. Laboratory Corporation of America Holdings Recent Development
Table 65. F. Hoffmann-La Roche Company Information
Table 66. F. Hoffmann-La Roche Business Overview
Table 67. F. Hoffmann-La Roche Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. F. Hoffmann-La Roche Hereditary Disease Testing Product Portfolio
Table 69. F. Hoffmann-La Roche Recent Development
Table 70. Quest Diagnostics Company Information
Table 71. Quest Diagnostics Business Overview
Table 72. Quest Diagnostics Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Quest Diagnostics Hereditary Disease Testing Product Portfolio
Table 74. Quest Diagnostics Recent Development
Table 75. CooperSurgical Company Information
Table 76. CooperSurgical Business Overview
Table 77. CooperSurgical Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. CooperSurgical Hereditary Disease Testing Product Portfolio
Table 79. CooperSurgical Recent Development
Table 80. Agilent Technologies Company Information
Table 81. Agilent Technologies Business Overview
Table 82. Agilent Technologies Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Agilent Technologies Hereditary Disease Testing Product Portfolio
Table 84. Agilent Technologies Recent Development
Table 85. Thermo Fisher Scientific Company Information
Table 86. Thermo Fisher Scientific Business Overview
Table 87. Thermo Fisher Scientific Hereditary Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Thermo Fisher Scientific Hereditary Disease Testing Product Portfolio
Table 89. Thermo Fisher Scientific Recent Development
Table 90. Twist Bioscience Company Information
Table 91. Twist Bioscience Business Overview
Table 92. Twist Bioscience Hereditary Disease Testing Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Twist Bioscience Hereditary Disease Testing Product Portfolio
Table 94. Twist Bioscience Recent Development
Table 95. Sophia Genetics Company Information
Table 96. Sophia Genetics Business Overview
Table 97. Sophia Genetics Hereditary Disease Testing Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Sophia Genetics Hereditary Disease Testing Product Portfolio
Table 99. Sophia Genetics Recent Development
Table 100. Fulgent Genetic Company Information
Table 101. Fulgent Genetic Business Overview
Table 102. Fulgent Genetic Hereditary Disease Testing Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Fulgent Genetic Hereditary Disease Testing Product Portfolio
Table 104. Fulgent Genetic Recent Development
Table 105. Medgenome Company Information
Table 106. Medgenome Business Overview
Table 107. Medgenome Hereditary Disease Testing Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Medgenome Hereditary Disease Testing Product Portfolio
Table 109. Medgenome Recent Development
Table 110. CENTOGENE Company Information
Table 111. CENTOGENE Business Overview
Table 112. CENTOGENE Hereditary Disease Testing Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. CENTOGENE Hereditary Disease Testing Product Portfolio
Table 114. CENTOGENE Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Authors List of This Report
Table 117. Secondary Sources
Table 118. Primary Sources
List of Figures
Figure 1. Hereditary Disease Testing Product Image
Figure 2. Global Hereditary Disease Testing Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Hereditary Disease Testing Market Size (2021-2032) & (US$ Million)
Figure 4. Global Hereditary Disease Testing Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Hereditary Cancer Testing Image
Figure 8. Hereditary Non-cancer Testing Image
Figure 9. Global Hereditary Disease Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Hereditary Disease Testing Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Hereditary Disease Testing Sales Value Share by Type (2021-2032)
Figure 12. Hospital Image
Figure 13. Clinic Image
Figure 14. Laboratory Image
Figure 15. Others Image
Figure 16. Global Hereditary Disease Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 17. Global Hereditary Disease Testing Sales Value Share 2021 VS 2025 VS 2032
Figure 18. Global Hereditary Disease Testing Sales Value Share by Application (2021-2032)
Figure 19. Global Hereditary Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 20. Global Hereditary Disease Testing Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 21. North America Hereditary Disease Testing Sales Value (2021-2032) & (US$ Million)
Figure 22. North America Hereditary Disease Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 23. Europe Hereditary Disease Testing Sales Value (2021-2032) & (US$ Million)
Figure 24. Europe Hereditary Disease Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Asia-Pacific Hereditary Disease Testing Sales Value (2021-2032) & (US$ Million)
Figure 26. Asia-Pacific Hereditary Disease Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 27. South America Hereditary Disease Testing Sales Value (2021-2032) & (US$ Million)
Figure 28. South America Hereditary Disease Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 29. Middle East & Africa Hereditary Disease Testing Sales Value (2021-2032) & (US$ Million)
Figure 30. Middle East & Africa Hereditary Disease Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 31. USA Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 32. USA Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 33. USA Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 34. Canada Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 35. Canada Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 36. Canada Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 37. Mexico Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 38. Mexico Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 39. Mexico Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 40. Germany Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. Germany Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. Germany Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. France Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. France Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. France Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. U.K. Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. U.K. Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. U.K. Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. Italy Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. Italy Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. Italy Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. Spain Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. Spain Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. Spain Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. Russia Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. Russia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. Russia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Netherlands Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Netherlands Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Netherlands Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Nordic Countries Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Nordic Countries Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. China Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. China Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. China Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Japan Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Japan Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Japan Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. South Korea Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. South Korea Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. South Korea Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. India Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. India Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. India Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. Australia Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. Australia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. Australia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. Southeast Asia Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. Southeast Asia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. Brazil Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. Brazil Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. Brazil Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Argentina Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Argentina Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Argentina Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Chile Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Chile Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Chile Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Colombia Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Colombia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Colombia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Peru Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Peru Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Peru Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Saudi Arabia Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Saudi Arabia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Israel Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Israel Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Israel Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. UAE Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. UAE Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. UAE Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Turkey Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Turkey Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Turkey Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. Iran Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. Iran Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. Iran Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. Egypt Hereditary Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. Egypt Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. Egypt Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Years Considered
Figure 116. Research Process
Figure 117. Key Executives Interviewed
Scope & coverage.
Types
- Hereditary Cancer Testing
- Hereditary Non-cancer Testing
Applications
- Hospital
- Clinic
- Laboratory
- Others
Companies covered
- Myriad Genetics
- Invitae
- Illumina
- Natera
- Laboratory Corporation of America Holdings
- F. Hoffmann-La Roche
- Quest Diagnostics
- CooperSurgical
- Agilent Technologies
- Thermo Fisher Scientific
- Twist Bioscience
- Sophia Genetics
- Fulgent Genetic
- Medgenome
- CENTOGENE
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hereditary Disease Testing Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hereditary Disease Testing Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Hereditary Disease Testing Market Dynamics
- 2.1 Hereditary Disease Testing Industry Trends
- 2.2 Hereditary Disease Testing Industry Drivers
- 2.3 Hereditary Disease Testing Industry Opportunities and Challenges
- 2.4 Hereditary Disease Testing Industry Restraints
3 Hereditary Disease Testing Market by Company
- 3.1 Global Hereditary Disease Testing Company Revenue Ranking in 2025
- 3.2 Global Hereditary Disease Testing Revenue by Company (2021-2026)
- 3.3 Global Hereditary Disease Testing Company Ranking (2024-2026)
- 3.4 Global Hereditary Disease Testing Company Manufacturing Base and Headquarters
- 3.5 Global Hereditary Disease Testing Company Product Type and Application
- 3.6 Global Hereditary Disease Testing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Hereditary Disease Testing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Hereditary Disease Testing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Hereditary Disease Testing Market by Type
- 4.1 Hereditary Disease Testing Type Introduction
- 4.1.1 Hereditary Cancer Testing
- 4.1.2 Hereditary Non-cancer Testing
- 4.2 Global Hereditary Disease Testing Sales Value by Type
- 4.2.1 Global Hereditary Disease Testing Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hereditary Disease Testing Sales Value by Type (2021-2032)
- 4.2.3 Global Hereditary Disease Testing Sales Value Share by Type (2021-2032)
5 Hereditary Disease Testing Market by Application
- 5.1 Hereditary Disease Testing Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Laboratory
- 5.1.4 Others
- 5.2 Global Hereditary Disease Testing Sales Value by Application
- 5.2.1 Global Hereditary Disease Testing Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hereditary Disease Testing Sales Value by Application (2021-2032)
- 5.2.3 Global Hereditary Disease Testing Sales Value Share by Application (2021-2032)
6 Hereditary Disease Testing Regional Value Analysis
- 6.1 Global Hereditary Disease Testing Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hereditary Disease Testing Sales Value by Region (2021-2032)
- 6.2.1 Global Hereditary Disease Testing Sales Value by Region: 2021-2026
- 6.2.2 Global Hereditary Disease Testing Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hereditary Disease Testing Sales Value (2021-2032)
- 6.3.2 North America Hereditary Disease Testing Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Hereditary Disease Testing Sales Value (2021-2032)
- 6.4.2 Europe Hereditary Disease Testing Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Hereditary Disease Testing Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Hereditary Disease Testing Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Hereditary Disease Testing Sales Value (2021-2032)
- 6.6.2 South America Hereditary Disease Testing Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Hereditary Disease Testing Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Hereditary Disease Testing Sales Value Share by Country, 2025 VS 2032
7 Hereditary Disease Testing Country-level Value Analysis
- 7.1 Global Hereditary Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Hereditary Disease Testing Sales Value by Country (2021-2032)
- 7.2.1 Global Hereditary Disease Testing Sales Value by Country (2021-2026)
- 7.2.2 Global Hereditary Disease Testing Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.7.2 France Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.14.2 China Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.17.2 India Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Hereditary Disease Testing Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Hereditary Disease Testing Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Hereditary Disease Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Myriad Genetics
- 8.1.1 Myriad Genetics Company Information
- 8.1.2 Myriad Genetics Business Overview
- 8.1.3 Myriad Genetics Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.1.4 Myriad Genetics Hereditary Disease Testing Product Portfolio
- 8.1.5 Myriad Genetics Recent Developments
- 8.2 Invitae
- 8.2.1 Invitae Company Information
- 8.2.2 Invitae Business Overview
- 8.2.3 Invitae Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.2.4 Invitae Hereditary Disease Testing Product Portfolio
- 8.2.5 Invitae Recent Developments
- 8.3 Illumina
- 8.3.1 Illumina Company Information
- 8.3.2 Illumina Business Overview
- 8.3.3 Illumina Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.3.4 Illumina Hereditary Disease Testing Product Portfolio
- 8.3.5 Illumina Recent Developments
- 8.4 Natera
- 8.4.1 Natera Company Information
- 8.4.2 Natera Business Overview
- 8.4.3 Natera Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.4.4 Natera Hereditary Disease Testing Product Portfolio
- 8.4.5 Natera Recent Developments
- 8.5 Laboratory Corporation of America Holdings
- 8.5.1 Laboratory Corporation of America Holdings Company Information
- 8.5.2 Laboratory Corporation of America Holdings Business Overview
- 8.5.3 Laboratory Corporation of America Holdings Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.5.4 Laboratory Corporation of America Holdings Hereditary Disease Testing Product Portfolio
- 8.5.5 Laboratory Corporation of America Holdings Recent Developments
- 8.6 F. Hoffmann-La Roche
- 8.6.1 F. Hoffmann-La Roche Company Information
- 8.6.2 F. Hoffmann-La Roche Business Overview
- 8.6.3 F. Hoffmann-La Roche Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.6.4 F. Hoffmann-La Roche Hereditary Disease Testing Product Portfolio
- 8.6.5 F. Hoffmann-La Roche Recent Developments
- 8.7 Quest Diagnostics
- 8.7.1 Quest Diagnostics Company Information
- 8.7.2 Quest Diagnostics Business Overview
- 8.7.3 Quest Diagnostics Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.7.4 Quest Diagnostics Hereditary Disease Testing Product Portfolio
- 8.7.5 Quest Diagnostics Recent Developments
- 8.8 CooperSurgical
- 8.8.1 CooperSurgical Company Information
- 8.8.2 CooperSurgical Business Overview
- 8.8.3 CooperSurgical Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.8.4 CooperSurgical Hereditary Disease Testing Product Portfolio
- 8.8.5 CooperSurgical Recent Developments
- 8.9 Agilent Technologies
- 8.9.1 Agilent Technologies Company Information
- 8.9.2 Agilent Technologies Business Overview
- 8.9.3 Agilent Technologies Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.9.4 Agilent Technologies Hereditary Disease Testing Product Portfolio
- 8.9.5 Agilent Technologies Recent Developments
- 8.10 Thermo Fisher Scientific
- 8.10.1 Thermo Fisher Scientific Company Information
- 8.10.2 Thermo Fisher Scientific Business Overview
- 8.10.3 Thermo Fisher Scientific Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.10.4 Thermo Fisher Scientific Hereditary Disease Testing Product Portfolio
- 8.10.5 Thermo Fisher Scientific Recent Developments
- 8.11 Twist Bioscience
- 8.11.1 Twist Bioscience Company Information
- 8.11.2 Twist Bioscience Business Overview
- 8.11.3 Twist Bioscience Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.11.4 Twist Bioscience Hereditary Disease Testing Product Portfolio
- 8.11.5 Twist Bioscience Recent Developments
- 8.12 Sophia Genetics
- 8.12.1 Sophia Genetics Company Information
- 8.12.2 Sophia Genetics Business Overview
- 8.12.3 Sophia Genetics Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.12.4 Sophia Genetics Hereditary Disease Testing Product Portfolio
- 8.12.5 Sophia Genetics Recent Developments
- 8.13 Fulgent Genetic
- 8.13.1 Fulgent Genetic Company Information
- 8.13.2 Fulgent Genetic Business Overview
- 8.13.3 Fulgent Genetic Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.13.4 Fulgent Genetic Hereditary Disease Testing Product Portfolio
- 8.13.5 Fulgent Genetic Recent Developments
- 8.14 Medgenome
- 8.14.1 Medgenome Company Information
- 8.14.2 Medgenome Business Overview
- 8.14.3 Medgenome Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.14.4 Medgenome Hereditary Disease Testing Product Portfolio
- 8.14.5 Medgenome Recent Developments
- 8.15 CENTOGENE
- 8.15.1 CENTOGENE Company Information
- 8.15.2 CENTOGENE Business Overview
- 8.15.3 CENTOGENE Hereditary Disease Testing Revenue and Gross Margin (2021-2026)
- 8.15.4 CENTOGENE Hereditary Disease Testing Product Portfolio
- 8.15.5 CENTOGENE Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst